

Asst. Prof. TOLGA SÜTLÜ

Web: <https://avesis.acibadem.edu.tr/Tolga.Sutlu>

International Researcher IDs

ScholarID: 6iDVVIUAAAAJ

ORCID: 0000-0002-7813-8734

Publons / Web Of Science ResearcherID: E-1190-2012

ScopusID: 24077626900

Yoksis Researcher ID: 258642



Biography

Dr. Tolga Sütü received his Bachelor's Degree in Biological Sciences and Bioengineering from Sabanci University in 2004. Continuing his postgraduate education in Sweden, he received his Ph.D. in Medical Science from Karolinska Institutet in 2012 and carried out his postdoctoral work at the Center for Hematology and Regenerative Medicine at Karolinska University Hospital. Upon his return to Turkey, he worked as a research group leader at Sabanci University between 2014-2019 and later as a faculty member in the Department of Molecular Biology and Genetics at Boğaziçi University until 2023.

He has been serving as a board member at the Turkish Society of Immunology since 2016. His notable awards include Science Academy Young Scientists Award Program (BAGEP) in 2017, the METU Parlar Foundation Technology Incentive Award in 2018, the Molecular Cancer Research Association's Basic Cancer Researcher of the Year award, and the JCI International's 10 Outstanding Young Persons of Turkey award in 2019.

Education Information

- I. Doctorate, Karolinska Institutet (Karolinska Institute), Karolinska University Hospital Huddinge, Department of Medicine, Sweden 2007 - 2012
- II. Postgraduate, Karolinska Institutet (Karolinska Institute), Stockholm Research School in Molecular Life Sciences, Stockholm Research School in Molecular Life Sciences, Sweden 2005 - 2006
- III. Undergraduate, Sabanci University, Faculty Of Engineering And Natural Sciences, Department Of Biological Sciences, Turkey 2000 - 2004

Foreign Languages

- I. English, C2 Mastery

Dissertations

- I. Doctorate, Expansion and genetic modification of human natural killer cells for adoptive immunotherapy of cancer,

Research Areas

Biotechnology, Immunology, Genetic Engineering, Molecular Biology of Cancer

Academic Titles / Tasks

- I. Assistant Professor, Bogazici University, Faculty Of Arts And Sciences, Department Of Molecular Biology And Genetics, 2019 - 2023
- II. Assistant Professor, Sabanci University, Nanotechnology Application And Research Center, 2014 - 2019

Courses

- I. Molecular and Translational Biomedicine, Postgraduate, 2023 - 2024
- II. Advanced Molecular and Cellular Biology, Postgraduate, 2023 - 2024
- III. Introduction to Cell Biology, Undergraduate, 2021 - 2022, 2020 - 2021
- IV. Advanced Genetics, Postgraduate, 2020 - 2021
- V. Special Topics: Cell and Gene Therapy, Postgraduate, 2019 - 2020
- VI. Immunology, Undergraduate, 2020 - 2021, 2019 - 2020
- VII. Life on Earth, Undergraduate, 2016 - 2017

Advising Theses

- I. Sütlü T., Dissecting the crosstalk between inhibitory receptor signaling and the T cell receptor in natural killer cells, Postgraduate, E.ZEYNEP(Student), 2022
- II. Sütlü T., Co-receptor mediated regulation of T cell receptor signalling in natural killer cells, Postgraduate, Z.SENA(Student), 2022
- III. Sütlü T., Çetiner M. S., Development of a pseudovirus-based assay for analysis of neutralizing activity against SARS-CoV-2, Doctorate, C.PAMUKCU(Student), 2021
- IV. Sütlü T., Erman M. B., Functional analysis of a novel mutation in the cd70 gene leading to primary immunodeficiency disease, Postgraduate, S.BEDİR(Student), 2020
- V. Sütlü T., Yüce M., Investigating the role of coiled-coil domain containing 124 (CCDC124) in innate antiviral immune response, Postgraduate, A.ERTUNGA(Student), 2019
- VI. Sütlü T., A systemic comparison of different chimeric antigen receptor (car) designs for retargeting of NK-92 cells against tumor antigens, Postgraduate, E.ÇELİK(Student), 2019
- VII. Sütlü T., A novel approach in cancer immunotherapy: Natural killer cells expressing t cell receptors, Postgraduate, A.PARLAR(Student), 2017
- VIII. Sütlü T., Mapping intracellular immune responses against lentiviral vectors in natural killer cells using genome scale CRISPR knockout, Postgraduate, A.SARAÇ(Student), 2017
- IX. Sütlü T., Erman M. B., Intracellular immunodynamics of lentiviral gene delivery in human natural killer cells, Doctorate, E.CANAN(Student), 2017

-
- I. **TCR-NK Cells: A Novel Source for Adoptive Immunotherapy of Cancer**
Karahan Z. S., Aras M., Sutlu T.
TURKISH JOURNAL OF HEMATOLOGY, vol.40, no.1, pp.1-10, 2023 (SCI-Expanded)
 - II. **Human immunodeficiency virus type 1 impairs sumoylation**
Mete B., Pekbilir E., Bilge B. N., Georgiadou P., Celik E., Sutlu T., Tabak F., Sahin U.
LIFE SCIENCE ALLIANCE, vol.5, no.6, 2022 (SCI-Expanded)
 - III. **Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma**
Nahi H., Chrobok M., Meinke S., Gran C., Marquardt N., Afram G., Sutlu T., Gilljam M., Stellan B., Wagner A. K., et al.
CELL REPORTS MEDICINE, vol.3, no.2, 2022 (SCI-Expanded)
 - IV. **Decline of humoral immune responses after natural SARS-CoV-2 infection can be efficiently reversed by vaccination**
ÖKTELİK F. B., YILMAZ V., GELMEZ M. Y., AKDENİZ N., Pamukcu C., Sutlu T., KÖSE M., TÜZÜN E., DENİZ G.
CANADIAN JOURNAL OF MICROBIOLOGY, vol.68, pp.543-550, 2022 (SCI-Expanded)
 - V. **Development of a pseudovirus-based assay for analysis of neutralizing activity against SARS-CoV-2 in convalescent plasma**
Aras M., Pamukcu C., Celik E., Ergun E. Z., Karahan Z. S., Turkoz G., Eren C., SİLİ U., Bilgin H., Suder I., et al.
EUROPEAN JOURNAL OF IMMUNOLOGY, pp.368, 2021 (SCI-Expanded)
 - VI. **A colorimetric pseudovirus-based assay using secreted embryonic alkaline phosphatase for analysis of neutralizing activity against SARS-CoV-2**
Pamukcu C., Aras M., Celik E., Ergun E. Z., Karahan Z. S., Sutlu T.
EUROPEAN JOURNAL OF IMMUNOLOGY, pp.112, 2021 (SCI-Expanded)
 - VII. **Characterization of zika virus infection of human fetal cardiac mesenchymal stromal cells**
Rossi F., Josey B., Sayitoglu E. C., Potens R., Sultu T., Duru A. D., Beljanski V.
PLOS ONE, vol.15, no.9, 2020 (SCI-Expanded)
 - VIII. **Natural killer cells genetically modified to overexpress DNAM-1 exert enhanced antitumor responses against CD112/CD155+sarcomas and other malignancies.**
Sayitoglu E. C., Chrobok M., Georgoudaki A., Josey B. J., Hartman M., Vallabhaneni E., Herekar R., Bergeron S., Krueger R., Sutlu T., et al.
CANCER IMMUNOLOGY RESEARCH, no.4, pp.64-65, 2020 (SCI-Expanded)
 - IX. **Engineering antigen-specific natural killer cells against the melanoma-associated antigen tyrosinase via TCR gene transfer.**
Parlar A., Sayitoglu E. C., Pamukcu C., Georgoudaki A., Ozkazanc D., Aras M., Josey B., Chrobok M., Branecki S., Zahedimaram P., et al.
CANCER IMMUNOLOGY RESEARCH, no.4, pp.49-50, 2020 (SCI-Expanded)
 - X. **Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D**
Sayitoglu E. C., Georgoudaki A., Chrobok M., Ozkazanc D., Josey B. J., Arif M., Kusser K., Hartman M., Chinn T. M., Potens R., et al.
FRONTIERS IN IMMUNOLOGY, vol.11, 2020 (SCI-Expanded)
 - XI. **Myeloid maturation potentiates STAT3-mediated atypical IFN-gamma signaling and upregulation of PD-1 ligands in AML and MDS**
YÖYEN ERMİŞ D., Tunalı G., Tavukcuoglu E., Horzum U., Ozkazanc D., Sutlu T., BÜYÜKAŞIK Y., ESENDAĞLI G.
SCIENTIFIC REPORTS, vol.9, 2019 (SCI-Expanded)
 - XII. **Plasmonic Selection of ssDNA Aptamers against Fibroblast Growth Factor Receptor**
KURT H., Eyupoglu A. E., Sutlu T., Budak H., Yuce M.
ACS COMBINATORIAL SCIENCE, vol.21, no.8, pp.578-587, 2019 (SCI-Expanded)
 - XIII. **Engineering antigen-specific NK cell lines against the melanoma-associated antigen tyrosinase via TCR gene transfer**
Parlar A., Sayitoglu E. C., Ozkazanc D., Georgoudaki A., Pamukcu C., Aras M., Josey B. J., Chrobok M., Branecki S., Zahedimaram P., et al.

- EUROPEAN JOURNAL OF IMMUNOLOGY, vol.49, no.8, pp.1278-1290, 2019 (SCI-Expanded)
- XIV. **Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells**
Chrobok M., Dahlberg C. I. M., Sayitoglu E. C., Beljanski V., Nahi H., Gilljam M., Stellan B., Sutlu T., Duru A. D., Alici E.
CANCERS, vol.11, no.1, 2019 (SCI-Expanded)
- XV. **Circulating LL37 targets plasma extracellular vesicles to immune cells and intensifies Behcet's disease severity**
Kahraman T., Gucluler G., Simsek I., Yagci F. C., Yildirim M., ÖZEN C., Dinc A., Gursel M., Ikromzoda L., Sutlu T., et al.
JOURNAL OF EXTRACELLULAR VESICLES, vol.6, 2017 (SCI-Expanded)
- XVI. **Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma**
Duru A. D., Sutlu T., Wallblom A., Uttervall K., Lund J., Stellan B., Gahrton G., Nahi H., Alici E.
PLOS ONE, vol.10, no.9, 2015 (SCI-Expanded)
- XVII. **Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model**
Bestas B., Moreno P. M. D., Blomberg K. E. M., Mohammad D. K., Saleh A. F., Sutlu T., Nordin J. Z., Guterstam P., Gustafsson M. O., Kharazi S., et al.
JOURNAL OF CLINICAL INVESTIGATION, vol.124, no.9, pp.4067-4081, 2014 (SCI-Expanded)
- XVIII. **In search of the molecular consequences of 8p21 deletion in multiple myeloma: commentary on Gmidene et al**
Sutlu T., Alici E., Gahrton G., Nahi H.
MEDICAL ONCOLOGY, vol.30, no.2, 2013 (SCI-Expanded)
- XIX. **Inhibition of Intracellular Antiviral Defense Mechanisms Augments Lentiviral Transduction of Human Natural Killer Cells: Implications for Gene Therapy**
Sutlu T., Nystrom S., Gilljam M., Stellan B., Applequist S. E., Alici E.
HUMAN GENE THERAPY, vol.23, no.10, pp.1090-1100, 2012 (SCI-Expanded)
- XX. **Clinical impact of chromosomal aberrations in multiple myeloma**
Nahi H., Sutlu T., Jansson M., Alici E., Gahrton G.
JOURNAL OF INTERNAL MEDICINE, vol.269, no.2, pp.137-147, 2011 (SCI-Expanded)
- XXI. **Ex vivo expansion of natural killer cells: a question of function**
Sutlu T., Alici E.
CYTOTHERAPY, vol.13, no.6, pp.767-768, 2011 (SCI-Expanded)
- XXII. **Constitutional inv(3) in myelodysplastic syndromes**
Gahrton C., Nahi H., Jansson M., Wallblom A., Alici E., Sutlu T., Samuelsson J., Gahrton G.
LEUKEMIA RESEARCH, vol.34, no.12, pp.1627-1629, 2010 (SCI-Expanded)
- XXIII. **Suicide gene therapy for graft-versus-host disease**
Georgoudaki A., Sutlu T., Alici E.
IMMUNOTHERAPY, vol.2, no.4, pp.521-537, 2010 (SCI-Expanded)
- XXIV. **Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor**
Sutlu T., Stellan B., Gilljam M., Quezada H. C., Nahi H., Gahrton G., Alici E.
CYTOTHERAPY, vol.12, no.8, pp.1044-1055, 2010 (SCI-Expanded)
- XXV. **Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a Phase I clinical study**
Barkholt L., Alici E., Conrad R., Sutlu T., Gilljam M., Stellan B., Christensson B., Guven H., Bjorkstrom N. K., Soderdahl G., et al.
IMMUNOTHERAPY, vol.1, no.5, pp.753-764, 2009 (SCI-Expanded)
- XXVI. **Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation**
Paul E., Sutlu T., Deneberg S., Alici E., Bjorkstrand B., Jansson M., Lerner R., Wallblom A., Gahrton G., Nahi H.
ONCOLOGY REPORTS, vol.22, no.1, pp.137-142, 2009 (SCI-Expanded)
- XXVII. **Natural killer cell-based immunotherapy in cancer: current insights and future prospects**
Sutlu T., Alici E.

- JOURNAL OF INTERNAL MEDICINE, vol.266, no.2, pp.154-181, 2009 (SCI-Expanded)
- XXVIII. **The prognostic significance of 8p21 deletion in multiple myeloma**
Sutlu T., Alici E., Jansson M., Wallblom A., Dilber M. S., Gahrton G., Nahi H.
BRITISH JOURNAL OF HAEMATOLOGY, vol.144, no.2, pp.266-268, 2009 (SCI-Expanded)
- XXIX. **Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components**
Alici E., Sutlu T., Boejrkstrand B., Gilljam M., Stellan B., Nahi H., Quezada H. C., Gahrton G., Ljunggren H., Dilber M. S.
BLOOD, vol.111, no.6, pp.3155-3162, 2008 (SCI-Expanded)
- XXX. **Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model**
Alici E., Konstantinidis K. V., Sutlu T., Aints A., Gahrton G., Ljunggren H., Dilber M. S.
EXPERIMENTAL HEMATOLOGY, vol.35, no.12, pp.1839-1846, 2007 (SCI-Expanded)
- XXXI. **Delivery of short interfering RNA using endosomolytic cell-penetrating peptides**
Lundberg P., El-Andaloussi S., Sutlu T., Johansson H., Langel U.
FASEB JOURNAL, vol.21, no.11, pp.2664-2671, 2007 (SCI-Expanded)
- XXXII. **Triticum durum metallothionein - Isolation of the gene and structural characterization of the protein using solution scattering and molecular modeling**
Bilecen K., Ozturk U., Duru A., Sutlu T., Petoukhov M., Svergun D., Koch M., Sezerman U., Cakmak I., Sayers Z.
JOURNAL OF BIOLOGICAL CHEMISTRY, vol.280, no.14, pp.13701-13711, 2005 (SCI-Expanded)

Refereed Congress / Symposium Publications in Proceedings

- I. **STAT3-mediated atypical IFN-gamma signaling modulates the PD-1 ligands in CD11b-positive subpopulation of MDS and AML cells**
YÖYEN ERMİŞ D., Tunali G., Tavukcuoglu E., Ozkazanc D., Sutlu T., BÜYÜKAŞIK Y., ESENDAĞLI G.
17th International Congress of Immunology of the International-Union-of-Immunological-Societies (IUIS), Beijing, China, 19 - 23 October 2019, pp.90
- II. **Engineering antigen-specific NK cells via TCR gene transfer: A novel source for adoptive immunotherapy**
Parlar A., Pamukcu C., Ozkazanc D., Aras M., Dahlberg C., Chrobok M., Zahedimaram P., Ikromzoda L., Sayitoglu E. C., Alici E., et al.
European-Society-of-Gene-and-Cell-Therapy (ESCGT) Congress, Berlin, Germany, 01 January 2017
- III. **Optimized genetic modification of primary human NK cells**
Wagner A. K., Chrobok M., Hussain A., Gilljam M., Dahlberg C. I. M., Sutlu T., Duru A. D., Nahi H., Lundqvist A., Ljunggren H., et al.
44th Annual Meeting of the Scandinavian-Society-for-Immunology (SSI), Stockholm, Sweden, 17 - 20 October 2017, pp.348
- IV. **Adaption of NK-92 cells to serum-free culture with inherent anti-tumor response: NK-92 cells stand strong in a serum-free milieu**
Chrobok M., Dahlberg C. I. M., Sayitoglu C., Nahi H., Sarhan D., Gilljam M., Stellan B., Sutlu T., Duru A. D., Alici E.
44th Annual Meeting of the Scandinavian-Society-for-Immunology (SSI), Stockholm, Sweden, 17 - 20 October 2017, pp.342
- V. **Innate immune sensors restrict lentiviral gene delivery to human natural killer cells: novel perspectives on the use of viral vectors**
Sayitoglu E. C., Duru A. D., Chrobok M., Chiang C., Parlar A., Senturk G. H., Erman B., Alici E., Sutlu T.
Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy (ESGCT) and Finnish-Society-of-Gene-Therapy (FSGT), Helsinki, Finland, 17 - 20 September 2015
- VI. **Multiple Myeloma patients with del(8)(p21) are more resistant to Bortezomib treatment**
Duru A. D., Sutlu T., Wallblom A., Uttervall K., Lund J., Stellan B., Gahrton G., Nahi H., Alici E.

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Turkey, 22 - 25 March 2015

- VII. **Personalized therapy for X-linked agammaglobulinemia (XLA) by oligonucleotide-induced splice-correction**
Bestas B., Moreno P. M. D., Blomberg K. E. M., Mohammad D. K., Saleh A. F., Sutlu T., Nordin J. Z., Guterstam P., Kharazi S., Behlke M. A., et al.
ESGCT and NVGCT Collaborative Congress, The Hague, Netherlands, 23 - 26 October 2014
- VIII. **Enhancement of lentiviral transduction efficiency by inhibition of intracellular anti-viral defense mechanisms**
Sutlu T., Nystrom S., Gilljam M., Stellan B., Applequist S. E., Alici E.
Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy/French-Society-of-Cell-and-Gene-Therapy, Versailles, France, 25 - 29 October 2012
- IX. **RNA THERAPEUTICS IN XLA - A NOVEL STRATEGY TO REPAIR BTK MUTATIONS**
Bestas B., Moreno P. M., Blomberg K. E. M., Berglof A., Gustafsson M. O., Mohammad D. K., Sutlu T., Lundin K. E., Asplund A. C., El-Andaloussi S., et al.
15th Biennial Meeting European-Society-for-Immunodeficiency (ESID), Florence, Italy, 3 - 06 October 2012, pp.165-166
- X. **Expansion of NK cells for cancer immunotherapy: from process optimization to clinical evaluation**
Sutlu T., Gahrton G., Alici E.
18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Milan, Italy, 22 - 25 October 2010, pp.1416
- XI. **Ex vivo expanded autologous natural killer cells as a novel therapeutic approach in multiple myeloma**
Alici E., Sutlu T., Bjokstrand B., Gilljam M., Stellan B., Nahi H., Quezada H. C., Gahrton G., Ljunggren H., Dilber M. S.
16th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Brugge, Belgium, 13 - 16 November 2008, pp.1183
- XII. **Natural killer cells kill syngeneic myeloma cells in C57Bl/KaLwRij upon adoptive transfer**
Alici E., Sutlu T., Gahrton G., Dilber S.
15th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Rotterdam, Netherlands, 27 - 30 October 2007, pp.992-993

Supported Projects

- I. Sütlu T., TUBITAK Project, Hedefe Özgü Pan-Kanser Terapiler, 2021 - 2025
- II. Sütlu T., TUBITAK Project, Melanom Antijenlerine Spesifik T Hücreleri Reseptörleri ile Modifiye Edilen Doğal Öldürücü Hücrelerin Kanser Aşısı Olarak Geliştirilmesi, 2020 - 2024
- III. Sütlu T., TUBITAK Project, Ülkemizde ve Dünyada Halk Sağlığını En Fazla Tehdit Eden HIV, HPV ve Influenza Kaynaklı Enfeksiyonlara Karşı Tanı Kitleri, İlaç Formülasyonları ve Aşısı Geliştirilmesi, 2020 - 2023
- IV. Sütlu T., Project Supported by Higher Education Institutions, COVID-19 konvelasan plazma vericilerinde oluşan antikor etkinliğinin belirlenmesi için psödovirüse dayalı nötralizasyon testi geliştirilmesi, 2020 - 2021
- V. Sütlu T., TUBITAK Project, Bevacizumab Etkin Maddeli Biyobenzer Ürünün Geliştirilmesi ve Üretilmesi, 2017 - 2019
- VI. Sütlu T., TUBITAK Project, Kanser İmmünoterapisi Hedef Moleküllerinin Keşfi İçin Hücresel Düzeyde Bir Tarama Testi, 2015 - 2018
- VII. TUBITAK Project, Viral vektörlerle gen aktarımında yeni yaklaşımlar (TUBİTAK 2232), 2016 - 2017
- VIII. Sütlu T., TUBITAK Project, Kanser İmmünoterapisinde Bir Nanotıp Uygulaması Olarak DK Hücreleri Tabanlı Eksozomlar, 2014 - 2017

Patent

- I. Sütü T., Enhanced gene delivery to natural killer cells, hematopoietic stem cells and macrophages, Patent, CHAPTER A Human Needs, The Invention Registration Number: EP3356524B1 , Standard Registration, 2021
- II. Sütü T., Natural killer (nk) cells expressing an antigen-specific functional t cell receptor (tcr) complex, methods for production thereof, and methods for therapeutic use thereof, Patent, CHAPTER A Human Needs, The Invention Recourse Number: PCT/US2018/012403 , Standard Registration, 2018

Activities in Scientific Journals

- I. TURKISH JOURNAL OF IMMUNOLOGY, Assistant Editor/Section Editor, 2021 - Continues

Memberships / Tasks in Scientific Organizations

- I. Turkish Society of Immunology, Board Member, 2016 - Continues, Turkey
- II. Molecular Biology Association of Turkey, Board Member, 2017 - 2020, Turkey

Scientific Consultations

- I. Acibadem Labmed, Project Consultancy, Acibadem Mehmet Ali Aydınlar University, Faculty Of Engineering And Natural Sciences, Molecular Biology And Genetics, Turkey, 2023 - Continues

Congress and Symposium Activities

- I. 12th Annual "Meet the Experts of Transplantation and Myeloma": EBMT and TCT, Invited Speaker, İstanbul, Turkey, 2024
- II. 1st International Acibadem Hematoimmunology Symposium, Invited Speaker, İstanbul, Turkey, 2024
- III. Bahçeşehir Üniversitesi LÖSEV Fayda Topluluğu Turuncu Günler: Kanser Farkındalığı Semineri, Invited Speaker, İstanbul, Turkey, 2024
- IV. Türk Hematoloji Derneği, 16. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedaviler Kongresi, Invited Speaker, Antalya, Turkey, 2024
- V. Türkiye Romatoloji Derneği, İmmünoromatoloji Sempozyumu 2024, Invited Speaker, Antalya, Turkey, 2024
- VI. Gebze Teknik Üniversitesi Moleküler Biyoloji ve Genetik Seminer Serisi, Invited Speaker, Kocaeli, Turkey, 2023
- VII. Türk İmmünoloji Derneği, 26. Ulusal İmmünoloji Kongresi, Invited Speaker, Ankara, Turkey, 2023
- VIII. Cerrahpaşa Romatoloji Derneği, 2. Genetik ve İmmünoloji Kampı, Invited Speaker, İstanbul, Turkey, 2023
- IX. Türk Hematoloji Derneği, Hücre ve Gen Tedavilerinde Güncel Durum Çalıştayı: CAR T Hücre Modeli, Invited Speaker, Ankara, Turkey, 2023

Awards

- I. Sütü T., Basic Cancer Researcher of the Year, Moleküler Kanser Araştırmaları Derneği, September 2018
- II. Sütü T., Teknoloji Teşvik Ödülü, Odtü Mustafa Parlar Vakfı, September 2018
- III. Sütü T., Bilim Akademisi Genç Bilim İnsanları Ödül Programı, Bilim Akademisi, September 2017